Lanchi Ventures leads $42m Series A round for Chinese biotech startup Allink
Chinese biotech startup Allink Biotherapeutics, which counts China’s publicly listed Junshi Biosciences among its angel investors, has closed a $42-million Series A round to fund the global clinical studies of its pipeline products, it announced on …